Diptoindonesin G antagonizes AR signaling and enhances the efficacy of antiandrogen therapy in prostate cancer is a research paper published in The Prostate (2022). On theSindex it has a DataRank of 0. It has been cited 3 times.
Scored on demand from live citation data
Linked data & code
DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?
FAIR checklist signals are shown for context only and do not affect DataRank scoring.
We only score data papers we can read in full — never from an abstract alone.
National Institutes of Health
Grant: P30 CA177558
National Institutes of Health
Grant: R01 CA157429
National Institutes of Health
Grant: R01 CA196634
National Institutes of Health
Grant: R01 CA256893
National Institutes of Health
Grant: R01 CA264652
NCI NIH HHS
Grant: R01 CA236356
NCI NIH HHS
Grant: T32 CA009135
National Institutes of Health
Grant: 5R01CA196634-10
Improving chemotherapy of castration-resistant prostate cancer.
National Institutes of Health
Grant: 5R01CA256893-04
Enhancing the efficacy of androgen signaling inhibitors in prostate cancer
National Institutes of Health
Grant: 5R01CA157429-12
Overcoming Drug Resistance of Castration-Resistant Prostate Cancer
National Institutes of Health
Grant: 5R01CA264652-05
Plk1 as a prognostic biomarker for prostate cancer
National Institutes of Health
Grant: 3P30CA177558-01S1
CTRP Supplement
FWCI
0.41
Citation Percentile
0.6%
Citation Trend
Fields of Study
MeSH Terms
Keywords
Sustainable Development Goals